|
|
|
|
|
|
|
Rexahn Pharmaceuticals- Inc. (RNN)
|
|
1.63 -0.11 (-6.32%)
|
06-20 16:00
|
|
Open:
|
1.75
|
Pre. Close:
|
1.74
|
|
High:
|
1.75
|
Low:
|
1.58
|
|
Volume:
|
601,447
|
Market Cap:
|
52M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
1.753 - 1.765
|
1.765 - 1.774
|
|
Low:
|
1.55 - 1.566
|
1.566 - 1.578
|
|
Close:
|
1.608 - 1.63
|
1.63 - 1.646
|
|
|
|
Technical analysis (as of: 2018-06-20 4:37:59 PM)
|
|
Overall:
|
|
|
Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.
|
|
Target:
|
Six months: 2.42  One year: 2.78
|
|
Support:
|
Support1: 1.58 Support2: 1.31
|
|
Resistance:
|
Resistance1:
2.07 Resistance2: 2.38
|
|
Pivot:
|
1.88
|
|
Moving Averages:
|
MA(5): 1.77 MA(20): 1.96
MA(100): 1.82 MA(250): 2.06
|
|
MACD:
|
MACD(12,26):
-0.07 Signal(12,26,9): -0.03
|
|
%K %D:
|
%K(14,3): 7.57 %D(3): 11.79
|
|
RSI:
|
RSI(14): 32.79
|
|
52-Week:
|
High: 3.19
Low: 1.42 Change(%): -45.8
|
|
Average Vol(K):
|
3-Month: 35063
10-Days 20527
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.RNN has closed above bottom band by 9.7%. Bollinger Bands are 45% wider than normal. The large width of the bands suggest high volatility as compared to RNN's normal range. The bands have been in this wide range for 10 bars. This is a sign that the current trend might continue.
|
|
|
Headline News
|
|
2018-05-17T08:00:00-04:00
3 Things In Biotech, May 16: Lilly's No Headache, Aerie Eye's A Finish, Rexahn Swaps In Pancreatic Cancer
2018-05-07T08:42:07-04:00
Rexahn Pharmaceuticals down 5% on Q1 results
2018-05-07T08:04:31-04:00
Rexahn Pharmaceuticals beats by $0.07
2018-02-14T08:00:00-05:00
Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment
2018-02-12T10:42:19-05:00
Rexahn's RX-3117 shows positive effect in mid-stage bladder cancer study
2018-02-12T09:23:12-05:00
Premarket Gainers as of 9:05 am (02/12/2018)
2018-02-11T09:58:43-05:00
Week In Review: Tsinghua University Invests $276 Million In Cambridge U.K. Biohub
2018-02-08T09:23:34-05:00
Rexahn Pharma teams up with Zhejiang Haichang Bio to develop RX-0201 for liver cancer; shares up 1% premarket
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
